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SchizophreniaRecent neuroanatomical pattern classiﬁcation studies have attempted to individually classify cases with psy-
chotic disorders using morphometric MRI data in an automated fashion. However, this approach has not been
tested in population-based samples, in which variable patterns of comorbidity and disease course are typical-
ly found. We aimed to evaluate the diagnostic accuracy (DA) of the above technique to discriminate between
incident cases of ﬁrst-episode schizophrenia identiﬁed in a circumscribed geographical region over a limited
period of time, in comparison with next-door healthy controls. Sixty-two cases of ﬁrst-episode schizophrenia
or schizophreniform disorder and 62 age, gender and educationally-matched controls underwent 1.5 T MRI
scanning at baseline, and were naturalistically followed-up over 1 year. T1-weighted images were used to
train a high-dimensional multivariate classiﬁer, and to generate both spatial maps of the discriminative mor-
phological patterns between groups and ROC curves. The spatial map discriminating ﬁrst-episode schizo-
phrenia patients from healthy controls revealed a complex pattern of regional volumetric abnormalities in
the former group, affecting fronto-temporal-occipital gray and white matter regions bilaterally, including
the inferior fronto-occipital fasciculus, as well as the third and lateral ventricles. However, an overall modest
DA (73.4%) was observed for the individual discrimination between ﬁrst-episode schizophrenia patients and
controls, and the classiﬁer failed to predict 1-year prognosis (remitting versus non-remitting course) of
ﬁrst-episode schizophrenia (DA=58.3%). In conclusion, using a “real world” sample recruited with epidemi-
ological methods, the application of a neuroanatomical pattern classiﬁer afforded only modest DA to classify
ﬁrst-episode schizophrenia subjects and next-door healthy controls, and poor discriminative power to
predict the 1-year prognosis of ﬁrst-episode schizophrenia.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Neuroanatomical pattern classiﬁcation is a new method for brain
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group comparisons and classiﬁcation of scans at an individual basishol use disorders identiﬁcation
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vier OA license.(Fan et al., 2007; Klöppel et al., 2012). Given the multivariate nature
of their statistical approach, and the possibility to employ both linear
and non-linear analysis models, these techniques afford improved
sensitivity to uncover complex morphological brain differences in com-
parison to other voxelwise methods (Fan et al., 2007). Moreover, once
the pattern of abnormalities which better discriminates two groups is
deﬁned, this morphological signature can be used to classify images at
an individual basis, and measures of diagnostic accuracy (DA) can be
obtained (Fan et al., 2007; Klöppel et al., 2012). Thus, the use of pattern
classiﬁcation methods is nowadays thought to hold promise as an aux-
iliary tool to aid clinical diagnoses and outcome prediction in clinical
psychiatric practice (Klöppel et al., 2012).
Up until now, a limited number of structural magnetic resonance
imaging (MRI) studies have investigated the usefulness of pattern
classiﬁcation methods in the evaluation of schizophrenia, producing
variable results. Based on T1-weighted MRI scans, a few of those
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up to 91.8%) in the individual classiﬁcation of subjectswith both chronic
(Fan et al., 2007; Kawasaki et al., 2007; Sun et al., 2009; Yoon et al.,
2007) and ﬁrst-episode (Borgwardt et al., in press; Pohl and Sabuncu,
2009; Takayanagi et al., 2010, 2011) schizophrenia against controls,
with sample sizes as small as 16 subjects per group (Kawasaki et al.,
2007; Pohl and Sabuncu, 2009). Also, Koutsouleris et al. (2009, 2012) —
using two different cohorts of individuals at an at-risk mental state
(ARMS) for the development of psychosis — found good discrimination
(accuracies of up to 92.3%) between ARMS and healthy individuals, as
well as to predict later conversion to full-blown psychosis after a
4-year follow-up period. However, more recent studies evaluating
larger samples of patients with ﬁrst-episode schizophrenia (Kasparek et
al., 2011) or more generally in ﬁrst-episode psychosis (Mourao-Miranda
et al., 2012) have found very modest between-group discrimination,
with classiﬁcation accuracies varying from 54% to 71%. Moreover,
Nieuwenhuis et al. (2012), in the largest study of neuroanatomical pat-
tern classiﬁcation in schizophrenia published so far, have also achieved
a modest classiﬁcation accuracy of only up to 71.4% when comparing
two independent samples of, respectively, 128 (training sample, average
duration of illness of 10.3 years) and 155 (validation sample, average du-
ration of illness of 5.0 years) schizophrenia patients against matched
healthy controls.
Differences in the pipelines for image processing, feature extraction/
dimensionality reduction and pattern recognition methods, might at
least partly account for the above discrepancies across structural MRI
studies (Caprihan et al., 2008; Fan et al., 2007; Nieuwenhuis et al.,
2012; Pohl and Sabuncu, 2009). Nevertheless, conﬂicting ﬁndings
have been observed even across pattern classiﬁcation studies that
employed similar methods (Ardekani et al., 2011; Caprihan et al.,
2008; Castellani et al., 2012; Kasparek et al., 2011; Kawasaki et al.,
2007; Pohl and Sabuncu, 2009). Another potential factor that might
contribute for this heterogeneity of ﬁndings is the occurrence of biases
in the selection of cases and controls for eachMRI study. In this regard, it
is relevant to note that none of the investigations of schizophrenia
employing neuroanatomical pattern classiﬁcation to date have em-
ployed population-based approaches. In population-based studies, epi-
demiological methods are used to identify and recruit large and
representative samples of incident cases of ﬁrst-episode schizophrenia
and demographically-matched controls from the same, circumscribed
geographical area. The use of such designs to recruit participants is de-
sirable to reduce selection biases by ensuring that control individuals
truly represent the population from which the cases came from
(Grimes and Schulz, 2005; Lee et al., 2007).
In the present morphometric MRI study, a sample of patients with
ﬁrst-episode schizophrenia disorder and a group of demographically-
matched healthy controls were recruited using an epidemiologic ap-
proach. All subjects were followed-up naturalistically over a 1-year
period, with re-interviews carried out for diagnostic conﬁrmation
and assessment of prognosis (remitting versus non-remitting course).
A support-vector machine (SVM) classiﬁer was employed with the
following purposes: 1) to ascertain how distinguishable are schizo-
phrenia individuals from healthy controls at the time of FE using
T1-weighted MRI data acquired by 1.5 T scanning; 2) to evaluate
the performance of the classiﬁer in correctly predicting 1-year outcome
of ﬁrst-episode schizophrenia patients; and 3) to describe patterns
of complex morphological features signiﬁcantly associatedwith schizo-
phrenia at an early course of the illness.
2. Methods
2.1. Participants
Patients fulﬁllingDiagnostic and StatisticalManual forMental Disor-
ders, 4th edition, (DSM-IV) (American Psychiatric Association, 1994)
criteria for ﬁrst-episode schizophrenia/ schizophreniform disorderwere selected from a large sample of ﬁrst-episode psychosis individ-
uals who took part in a population-based case-control study investi-
gating the incidence of psychotic disorders in a circumscribed region
of São Paulo city, as previously described (Menezes et al., 2007;
Schaufelberger et al., 2007).
In the original epidemiological investigation, cases were identiﬁed
by active surveillance of all people that made contact for the ﬁrst time
with the mental healthcare services for that region between 2002 and
2005 due to a DSM-IV deﬁned psychotic disorder, regardless of its se-
verity (both outpatients and inpatients were recruited), duration of
illness or compliance to treatment. Patients with psychotic disorders
due to a general medical condition or substance-induced psychosis
were excluded. The research team provided general guidance to pa-
tients but they were referenced to treatment at the health services lo-
cated in the geographical region where they lived in.
For the present study, only the cases diagnosed as having schizo-
phrenia or schizophreniform disorder according to the Structured
Clinical Interview for DSM-IV (SCID) (First et al., 1995) were consid-
ered. From the total pool of 122 FE psychosis individuals identiﬁed
in the original neuroimaging investigation (Schaufelberger et al.,
2007), 62 fulﬁlled DSM-IV diagnostic criteria for schizophrenia or
schizophreniform disorder and thus constituted our study group. All
the individuals who remained under the schizophreniform disorder
diagnosis have achieved symptomatic remission before completing
6 months of illness duration during the follow-up (the only DSM-IV
criterion differentiating schizophrenia from schizohreniform disor-
der). In order to make it simpler for the reader, we decided to refer
to this group simply as “ﬁrst-episode schizophrenia” throughout the
manuscript. Details about the other psychosis cases not included in
the present investigation can be found elsewhere (Colombo et al.,
2012; Schaufelberger et al., 2007).
In order to obtain a population-based psychosis-free sample of
controls, next-door neighbors matched for age (within 5 years) and
genderwith psychosis caseswere initially screened to exclude the pres-
ence of psychotic symptoms using the Psychosis Screening Question-
naire (Bebbington and Nayani, 1995), and interviewed with the SCID
(non-patient version) for the assessment of other psychiatric disorders.
This approach resulted in an initial pool of 94 psychosis-free epidemio-
logical controls eligible for the neuroimaging investigation (Colombo et
al., 2012; Schaufelberger et al., 2007), fromwhich 5 individuals fulﬁlled
criteria for substancemisuse and 12 individuals fulﬁlled criteria for anx-
iety disorders (Colombo et al., 2012). For the present investigation,
aiming at selecting a homogeneous control sample to be used by the
classiﬁer, 62 age, gender and educationally-matched healthy individ-
uals free of any Axis I disorder (including lifetime substance abuse
and/ or dependence) other than speciﬁc phobia were selected and
formed our control group.
Other inclusion criteria for both schizophrenia cases and controls
were: (a) current age between 18 and 50 years; (b) residence for
6 months or more in deﬁned geographic areas of Sao Paulo. The ex-
clusion criteria consisted of: (a) history of head injury with loss of
consciousness; (b) presence of neurological disorders or any organic
disorders that could affect the central nervous system; (c) moderate
or severe mental retardation; and (d) contraindications for MRI
scanning.
Both ﬁrst-episode schizophrenia patients and healthy controls were
followed-up naturalistically over a 1-year period, with re-interviews
carried out for diagnostic conﬁrmation and assessment of prognosis
(remitting versus non-remitting course in the patients).
The study was approved by local ethics committees, and all subjects
provided informed written consent.
2.2. Clinical assessment scales
The severity of psychotic symptoms in the schizophrenia patients
was assessed using the Positive and Negative Syndrome Scale (PANSS)
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stance use with the Alcohol Use Disorders Identiﬁcation Test (AUDIT)
(Saunders et al., 1993) and the South Westminster Questionnaire
(Menezes et al., 1996); when appropriate, diagnoses of substance use
disorders in the psychoses groups were made using the SCID. A general
medical history, including medication use, was obtained directly with
each participant or with his/her relatives, and also through reviewing
of medical records.
All clinical assessment tools, including the SCID, were administered
to the participants both at baseline (T0) and at the 1-year follow-up
evaluation (T1). At T1, the outcome of ﬁrst-episode schizophrenia was
also determined using the DSM-IV course (remitting/ non-remitting)
speciﬁer (remitting course meaning a single episode in full remission
and absence of clinically important symptoms and a non-remitting
course meaning continuous, episodic or residual symptoms) (American
Psychiatric Association, 1994).
2.3. Neuroimaging data acquisition and analysis
Imaging data were acquired using two identical MRI scanners
(1.5 T GE Signa scanner, General Electric, Milwaukee WI, USA). Exactly
the same acquisition protocols were used (a T1-SPGR sequence pro-
viding 124 contiguous slices, voxel size=0.86×0.86×1.5 mm, TE=
5.2 ms, TR=21.7 ms, ﬂip angle=20, FOV=22 cm, matrix=256×192
pixels). The images of 41 ﬁrst-episode schizophrenia patients (66.1%)
and 38 healthy controls (61.3%) were acquired using Scanner #1.
All images were visually inspected by an experienced radiologist
with the purpose of identifying artifacts during image acquisition
and the presence of silent gross brain lesions.
Fig. 1 summarizes the pipeline of image processing and analysis
employed in the present study.
Initially, the T1-weighted images were pre-processed as follows:
skull-stripping; manual removal of the cerebellum in order to im-
prove the tissue segmentation of the temporal lobe; and correction
for signal inhomogeneities. The images were subsequently segment-
ed into their 3 principal brain tissue compartments (gray matter,
white matter, and cerebrospinal ﬂuid space) through an automated
routine. Images were then spatially registered to a Montreal Neuro-
logical Institute (MNI) single-subject brain template through two
steps (Fig. 1). Firstly, an afﬁne transformation was performed using
the FLIRT (FMRIB's Linear Image Registration Tool) tool of the FSLFig. 1. Routine employed for the processing a(FMRIB Software Library, http://www.fmrib.ox.ac.uk/fsl/ﬂirt) in order
to align the major brain structures to the MNI template, and also to
correct for differences in head positioning. Secondly, a robust method
for elastic registration called Deformable Registration via Attribute
Matching and Mutual-Saliency weighting (DRAMMS) (Ou et al., 2011)
was employed. The deformationﬁeld resulting from the spatial registra-
tion of each T1-weighted image to theMNI template was applied to the
segmented images in order to generate mass-preserved volumetric
maps, named Regional Analysis of Volumes Examined in Normalized
Space (RAVENS)maps of the graymatter, whitematter, and cerebrospi-
nal ﬂuid compartments (Shen and Davatzikos, 2003). An automated al-
gorithm was used to isolate the cerebral ventricles (lateral ventricles
and third ventricle) from the remaining cerebrospinal ﬂuid space,
resulting in a ventricular RAVENS map. In the RAVENS maps, the tissue
density reﬂects the amount of tissue present in each subject's image at a
given location, after mapping to the standardized template space (Shen
and Davatzikos, 2003). Thus, a region of decreased density indicates a
reduced volume in this structure, for example. Lastly, the RAVENS
maps (gray matter, white matter and ventricles) were corrected for
the total brain volume (given by the sum of all voxels of brain tissue
and cerebrospinal ﬂuid space) and smoothed with 8 mm Gaussian
kernels.
The gray matter, white matter and ventricular RAVENS maps were
used as inputs for a previously described and validated SVM-based
pattern classiﬁer named Classiﬁcation of Morphological Patterns Using
Adaptive Regional Elements (COMPARE) (Fan et al., 2007) (https://www.
rad.upenn.edu/sbia/software/index.html#compare). In this method,
voxelwise correlations between RAVENS maps and group membership
are used to identify voxels that are candidates to be useful for inter-
group discrimination. To achieve the necessary dimensionality reduc-
tion, a watershed segmentation algorithm is then used to group voxels
into regional clusters and to identify the most relevant features to clas-
siﬁcation (group discrimination) (Fan et al., 2007). This approach also
works as an initial feature selection step, reducing the initial dimension-
ality of the data frommillions of variables to a relatively small set of re-
gional volumetric measurements, which the subsequent classiﬁer can
handle successfully. In order to improve the spatial consistency of the
watershed-derived regional volumetric elements and also to minimize
the inclusion of voxels not relevant for the classiﬁcation (which might
reduce the discriminative power), the degree of agreement among all
features in its spatial neighborhood is computed by an intraclassnd analysis of T1-weighted MRI images.
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Pearson correlation coefﬁcient is employed (Fan et al., 2007). Here,
the voxel with the highest discriminative power in each watershed-
derived region is ﬁrst selected, and the neighboring voxels are in-
cluded as long as their inclusion will not decrease the discriminative
power of the regional feature. Finally, a feature-selection technique
based on SVM criteria is used to select a sub-set of the top-ranked
features that optimizes the performance of the classiﬁer, constituting
the “morphological signature” of each group under study which is
used by the classiﬁer (Fan et al., 2007). The COMPARE classiﬁer, then,
employs a non-linear SVM method to assign a class label to each
image under study (individual classiﬁcation of the MRI scans) through
a Gaussian radial basis function kernel.
Although other theoretical frameworks for pattern recognition
analyses are available (Caprihan et al., 2008; Kasparek et al., 2011;
Sun et al., 2009), SVM with sufﬁcient dimensionality reduction is cur-
rently one of the most widely employed pattern classiﬁcation models
in the study of neuropsychiatric disorders (Fan et al., 2007; Klöppel et
al., 2012; Koutsouleris et al., 2009; Mourao-Miranda et al., 2012;
Nieuwenhuis et al., 2012). SVM is a powerful patter classiﬁcation
method that works ﬁnding a line or “decision boundary” that better
separates two groups (Lao et al., 2004). This boundary may be
depicted either by a hyperplane — in the case of linear classiﬁers –
or by a more general hypersurface — when a non-linear SVM is
used — in the high-dimensional feature space where the vectors
representing each brain under study are projected (Lao et al., 2004).
Differently from other hyperplane-based classiﬁers, however, the
SVM focus its analysis on those brains (or vectors) that are more
closely located to or on the hypersurface separating the two groups,
which are called the “support vectors”, maximizing the distance be-
tween the nearest vectors of the two groups. Thus, a SVM classiﬁer in-
herently focuses on subtle between-group morphological differences
and not on gross differences that are easily identiﬁable (Lao et al.,
2004).
The diagnostic performance of the COMPARE classiﬁer in the indi-
vidual discrimination of ﬁrst-episode schizophrenia versus healthy
control subjects was estimated using the leave-one-out cross valida-
tion (LOOCV) method. In each LOOCV experiment, one subject was
ﬁrst selected as a testing subject, and the remaining subjects were
used for the entire adaptive regional feature extraction, feature selec-
tion, and training procedure. Then, the classiﬁcation result on the
testing subject using the trained SVM classiﬁer was compared with
the ground-truth class label, to evaluate the classiﬁcation perfor-
mance. By repeatedly leaving each subject out as a testing subject,
we obtained the average classiﬁcation rate from all of these LOOCV
experiments (Fan et al., 2007).
A high-dimensional spatial map of the brain regions that consti-
tute a pattern of brain tissue distribution characteristic of the ﬁrst-
episode schizophrenia group relative to healthy controls was generat-
ed by COMPARE as previously described and validated (Davatzikos et
al., 2005; Fan et al., 2007, 2008). For this purpose, this spatial feature
map shows how frequently a particular region/feature was selected
during all the LOOCV tests, displaying regional brain volume changes
as one follows the path of the abnormality score from positive
(patient-like) to negative (control-like). A scale ranging from 0 to 1 is
set for each region, reﬂecting the relative importance for between-
group discriminations based on the LOOCV experiments (Fan et al.,
2007). For example, a region in the spatial map with a value of 0.76
means that it was used in 76% of the LOOCV tests as a distinguishing fea-
ture between the two groups. The classiﬁer integrates volumetric mea-
surements from a number of brain regions in a multivariate nonlinear
statistical model that optimally separates ﬁrst-episode schizophrenia
patients from healthy controls. Thus, it is possible to determine which
brain regions contributed the most to the separation of the two groups,
that is, which dimensions in the high-dimensional space of regional
volumetric measurements have the highest discriminatory power,which collectively form a structural pattern. The anatomic location of
each resulting cluster was determined using a stereotaxic MNI atlas
(Oishi et al., 2011).
It is important to notice, however, that this discriminative mor-
phological pattern generated by the classiﬁer displays a set of brain
regions needed for between-group classiﬁcation, but not necessarily
all areas of regional brain volume differences between the groups
under study.
Two additional comparisons were conducted, respectively, aiming
to determine the performance of the SVM classiﬁer in the prediction
of 1-year prognosis of the ﬁrst-episode schizophrenia patients
(i.e., remitting versus non-remitting course), and also to assess the po-
tential inﬂuence of good prognosis cases in the discrimination power of
the classiﬁer for the schizophrenia versus healthy controls comparison:
- First-episode schizophrenia individuals who were remitted at T1
versus a subsample ofmatchednon-remitted schizophrenia patients
at T1;
- First-episode schizophrenia individuals excluding the patients
with remitting course at follow-up versusmatched healthy controls.
2.4. ROC curve analysis
The classiﬁcation scores obtained by the COMPARE analyses were
evaluated using a receiver operating characteristic (ROC) curve aiming
to visualize the diagnostic performance of the classiﬁer in each of the
pairwise comparisons and to calculate area under the curve (AUC)
measure.
Indices of diagnostic performance such as DA (overall classiﬁca-
tion rate), sensitivity, speciﬁcity, positive predictive value (PPV) and
negative predictive value (NPV) were calculated using a 2×2 contin-
gency table. In the ROC curves, the individual Z scores obtained by the
SVM classiﬁer were plotted in a graph according to the true positive
rate (Y axis, corresponding to the sensitivity measure) versus false
positive rate (X axis, corresponding to 1 — speciﬁcity) generated in
the group classiﬁcation (Metz, 2006). This procedure allowed us to
adjust the threshold used by the SVM classiﬁer according to the de-
sired sensitivity/ speciﬁcity relationship. We will report herein the
sensitivity and speciﬁcity values observed when the highest classiﬁ-
cation accuracy was achieved.
The AUC measure of a classiﬁer is equivalent to the probability
that the classiﬁer will rank a randomly chosen (truly) positive diag-
nosis higher than a randomly chosen negative diagnosis (Metz,
2006). Thus, the AUC provides an estimate of the discriminative
power of the classiﬁer for a given condition, regardless of both the
chosen threshold (classiﬁer's score which separates the 2 groups
under study) and the sample size of each group.
3. Results
3.1. Demographic and clinical details
Demographic and clinical data for both ﬁrst-episode schizophre-
nia individuals and healthy controls are summarized in Table 1.
No signiﬁcant difference was observed between the proportion of
schizophrenia patients and healthy controls examined using Scanners
#1 and #2 (chi-square=0.31, df=1, p=0.575).
Regarding comorbid psychiatric diagnoses other than substancemis-
use, 1 schizophrenia patient fulﬁlled criteria for speciﬁc phobia and two
patients had comorbid obsessive-compulsive disorder. From the 62
healthy controls, 3 individuals fulﬁlled criteria for speciﬁc phobia.
At the end of the 1-year follow-up period, from the 62 ﬁrst-episode
schizophrenia individuals with conﬁrmed diagnoses of schizophrenia
or schizophreniform disorder, 15 (24.2%) had a remitting course of
their psychotic symptoms (remitted subgroup), whereas 44 (71%)
showed recurrence or a continuous course (non-remitted subgroup),
Table 1
Demographic and clinical information for ﬁrst-episode schizophrenia patients and matched healthy controls.
SCH (n=62) HC (n=62)
Age (mean±sd) 27.74±8.00 28.32±7.85
Gender (no. males;%) 45 (72.6%) 45 (72.6%)
Years of Education (mean±sd) 8.58±3.88 10.19±4.12
Handedness (no. right-handed;%) 55 (88.7%) 60 (96.8%)
Substance misusea 22 (35.5%) -
Duration of Illness (days; mean±sd) 363.6±458.6 -
Duration of Untreated Psychosis (days; mean±sd) 267.6±450.0 -
Medication use at the MRI (n; %)
Antipsychotics 40 (64.5%) -
Mood stabilizersb 4 (6.5%) -
Antidepressants 8 (12.9%) -
SCH, schizophrenia/schizophreniform disorder; HC, healthy controls; MRI, magnetic resonance imaging.
a Number of patients with a positive diagnosis of DSM-IV substance use disorder (prevalence).
b Lithium, carbamazepine and/or sodium valproate/ divalproex.
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clinical and demographical details for both the remitted and non-
remitted subgroups of the schizophrenia sample. These subgroups did
not differ with regard to compliance to treatment at T1 (Table 2). As
expected, the non-remitted schizophrenia patients presented signiﬁ-
cantly higher mean total PANSS scores at T1 relative to the non-
remitted individuals (Table 2).
Thus, the two additional analyses with the COMPARE classiﬁer were
conducted as follows:
- First-episode schizophrenia individuals who were remitted at T1
(n=15) versus matched non-remitted schizophrenia patients at T1
(n=21);
- First-episode schizophrenia individuals excluding the patients
with remitting course at follow-up (n=44) versusmatched healthy
controls (n=57).
3.2. Diagnostic performance of the classiﬁer in ﬁrst-episode schizophrenia
against healthy controls
Table 3 and Fig. 2 show, respectively, thediagnosticmeasures andROC
curves from the comparisons between the ﬁrst-episode schizophrenia
group versus healthy controls.
Initially, the SVM classiﬁer attained modest discrimination between
the ﬁrst-episode schizophrenia and control individuals, with an overall
DA of 73.4% (Table 3 and Fig. 2). When this comparison was repeated
after excluding those schizophrenia patients who later showed a remit-
ting course (good prognosis) over the 1-year follow-up period, theTable 2
Demographic and clinical information of schizophrenia patients subgrouped according to r
Remitted (n=
Age at T0 (mean±sd) 25.00±7.30
Gender (no. males;%) 8 (53.3%)
Years of Education at T0 (mean±sd) 8.73±2.34
Handedness (no. right-handed;%) 14 (93.3%)
Substance misuse a 3 (20.0%)
Duration of Illness at T0 (days; média±DP) 238.1±205.2
Duration of Untreated Psychosis at T0 (days; média±DP) 129.8±187.3
Compliance to treatment at T1b 4 (26.7%)
Total PANSS scores at T0 (mean±sd) 43.53±8.94
Total PANSS scores at T1 (mean±sd) 37.07±6.56
Medication use at the MRI (n; %)
Antipsychotics 9 (60.0%)
Mood stabilizers c 1 (6.7%)
Antidepressants 1 (6.7%)
T0, baseline (moment of the ﬁrst-episode); T1, 1-year follow-up; PANSS, Positive and Nega
a Number of patients with a positive diagnosis of DSM-IV substance use disorder (preval
b Number of patients in continuum treatment (%).
c Lithium, carbamazepine and/or sodium valproate/ divalproex.classiﬁcation performance substantially worsened (Table 3 and Fig. 2),
with an overall DA of 64.3%.
3.3. Performance of the classiﬁer in predicting 1-year outcome of the
schizophrenia patients
The SVM classiﬁer showed a poor diagnostic performance in the
differentiation between ﬁrst-episode schizophrenia who were remit-
ted at T1 (n=15) versus matched non-remitted schizophrenia pa-
tients at T1 (n=21) using the baseline (T0) MRI scans only: AUC=
0.51, accuracy=58.3%, sensitivity=38.1%, speciﬁcity=86.7%, PPV=
80.0% and NPV=50.0% (Fig. 3).
3.4. High-dimensional discriminative morphological pattern between
ﬁrst-episode schizophrenia and control individuals
Fig. 4 shows the neuroanatomical pattern of morphological
(i.e., volumetric reduction or enlargement) abnormalities affecting the
gray matter, white matter and ventricular compartments of the ﬁrst-
episode schizophrenia used by the SVM classiﬁer to discriminate them
from the healthy controls.
This high-dimensional morphometric analysis revealed that the
diagnosis of ﬁrst-episode schizophrenia is associated with a complex
pattern of regional gray matter morphometric abnormalities, mostly
volumetric reductions, affecting bilaterally the dorsolateral and orbital
frontal cortices, temporal cortex and insula, and also the left posterior
cingulate cortex. In addition, an area of increased gray matter volume
was observed in the right anterior cingulate cortex of schizophreniaemission or non-remission after 1 year.
15) Non-Remitted (n=44) Statistical tests
28.80±8.30 t=−1.57, df=58, p=0.121
35 (79.5%) χ2=3.89, df=1, p=0.049
8.66±4.32 t=0.63, df=58, p=0.934
38 (86.4%) χ2=0.52, df=1, p=0.471
18 (40.9%) χ2=2.13, df=1, p=0.144
420.7±521.8 Mann–Whitney, p=0.508
331.7±510.4 Mann–Whitney, p=0.216
16 (36.4%) χ2=0.47, df=1, p=0.493
49.36±12.29 t=−1.69, df=58, p=0.097
49.59±12.40 t=−4.79, df=53, pb0.001
29 (65.9%) χ2=0.17, df=1, p=0.680
2 (4.5%) χ2=0.10, df=1, p=0.747
7 (15.9%) χ2=0.81, df=1, p=0.367
tive Syndrome Scale.
ence).
Table 3
Diagnostic performance of the SVM classiﬁer in the individual discrimination of ﬁrst-episode schizophrenia cases (SCH) versus healthy controls.
Pairwise Comparison AUCa Accuracy Morfological features b Sensitivity Speciﬁcity PPV NPV
SCH (N=62) XMatched Controls (n=62) 0.75 73.4% 69 79.0% 67.7% 71.0% 76.3%
SCH-NR (N=44) X Matched Controls (n=57) 0.61 64.3% 147 52.3% 73.7% 60.5% 66.6%
SCH, schizophrenia/schizophreniform disorder; NR, non-remitted at T1; PPV, positive predictive value; NPV, negative predictive value.
a Area under the curve;
b Number of morphological features used for the best classiﬁcation rate (accuracy).
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affecting bilateral fronto-limbic-occipital circuits were observed in the
schizophrenia patients relative to healthy controls. Enlargements of
the 3rd ventricle and the posterior (occipital) horn of the left lateral
ventricle were also observed as signiﬁcantly contributing to the diagno-
sis of ﬁrst-episode schizophrenia.
When the resulting spatial map is limited to the top 10% ranked
morphometric features used for classiﬁcation, the anatomical regions
most signiﬁcantly associated with the diagnosis of ﬁrst-episode
schizophrenia are: bilateral dorsolateral and orbital frontal cortices,
temporal cortex and temporal-occipital junction bilaterally, right an-
terior cingulate and left posterior cingulate cortices; fronto-temporal-
occipital white matter circuits; and enlargement of the third ventri-
cle. Fig. 5 shows a 3D rendering of the top 10% ranked morphometric
features used for classiﬁcation. Tables 4 and 5 present the top 10%
ranked regions of, respectively, gray and white matter volume abnor-
malities which contributed the most for the discrimination between
ﬁrst-episode schizophrenia and healthy controls.
4. Discussion
To our knowledge, the present study is the ﬁrst to evaluate the
diagnostic performance of a neuroanatomical pattern classiﬁer in a
sample of schizophrenia using an epidemiologic approach to recruit
both patients and controls. This is also the largest study conducted
so far with neuroanatomical pattern classiﬁcation in ﬁrst-episode
schizophrenia.
In regard to the individual classiﬁcation of single subjects, we ob-
served only a modest discrimination between ﬁrst-episode schizophre-
nia versus healthy controls, with diagnostic performance measures
(Table 3) similar or slightly better than those reported by the most re-
cent studies evaluating subjects with ﬁrst-episode schizophrenia
(Kasparek et al., 2011) or a group of more general ﬁrst-episode psycho-
sis (Mourao-Miranda et al., 2012). Our DA measures were also similar
to those reported in the largest study of neuroanatomical patternFig. 2. ROC curves for the comparisons between ﬁrst-episode schizophrenia individuals (SCH),classiﬁcation in schizophrenia published to date (Nieuwenhuis et al.,
2012),which evaluated two independent samples ofmore than 100 pa-
tients with mainly chronic schizophrenia versus matched controls.
However, a great heterogeneity ofﬁndings has been reported across dif-
ferent studies which have employed neuroanatomical pattern classiﬁ-
cation in schizophrenia to date (Ardekani et al., 2011; Borgwardt et
al., in press; Caprihan et al., 2008; Castellani et al., 2012; Fan et al.,
2007; Kasparek et al., 2011; Kawasaki et al., 2007; Nieuwenhuis et al.,
2012; Pohl and Sabuncu, 2009; Sun et al., 2009; Takayanagi et al.,
2010, 2011; Yoon et al., 2007). The adequate selection of relevant fea-
tures for between-group discrimination is one important methodologi-
cal step of neuroanatomical pattern classiﬁcation studies (Caprihan et
al., 2008; Fan et al., 2007). However, the stability of themodel generated
by the classiﬁer and how generalizable this model is to the full range of
schizophrenia patients in the general population relies heavily on anad-
equate sample size (Nieuwenhuis et al., 2012) and also on the method
employed for recruitment of cases and controls for the study (Grimes
and Schulz, 2005; Lee et al., 2007; Walsh et al., 2011).
Up until now, there has been a lack of studies applying pattern
classiﬁcation methods to the investigation of population-based sam-
ples of individuals with schizophrenia compared to healthy controls
recruited in the same catchment areas. Population-based designs
are likely to reduce selection biases by ensuring that control individ-
uals represent the population from which the cases came from, there-
fore providing a valid estimate of the exposure of interest in that
population (Grimes and Schulz, 2005; Lee et al., 2007). Psychiatric
case-controls investigations employing such approach for the recruit-
ment of study participants are known to yield results that differ from
those obtained when convenience samples are used (i.e. students and
employees of the research institution and/or subjects recruited
through advertisement) (Lee et al., 2007; Walsh et al., 2011). More-
over, population-based studies allow the inclusion of schizophrenia
individuals presenting with a widely variable range of symptom
severity and medium/long-term prognosis, as expected in the general
population of psychosis sufferers over time. This is particularlyschizophrenia patients with a non-remitting course at T1 (SCH-NR) and healthy controls.
Fig. 4. Discriminative pattern of volumetric abnormalities in patients with ﬁrst-episode schi
ventricles (C). Brain regions which contributed the most for between-group discriminatio
region for between-group discrimination is translated here in a scale ranging from −1 to
regions of volumetric increase in patients relative to controls, whereas the blue clusters (neg
are displayed in radiological convention (the left side of the brain corresponds to the right
Fig. 3. ROC curve for the comparison between remitted (SCH-R) and non-remitted
schizophrenia (SCH-NR) at T1 using the baseline (T0) images.
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aid in single-case diagnostic and prognosis evaluations in clinical psy-
chiatric practice, as “real world” patient samples are likely to display
different kinds of clinical comorbidities (such as substance use disorders),
as well as widely variable disease courses. Considering that schizophre-
nia patientswith a chronic course of their illness are expected to display
more widespreadmorphological brain abnormalities than ﬁrst-episode
patients (Bora et al., 2011), the fact thatwe found a degree of DA similar
to that reported in the large, representative schizophrenia sample
recruited by Nieuwenhuis et al. (2012) reinforces the notion that
population-based designs provide a valid estimate of the exposure of
interest in the general population.
It is particularly intriguing that the present study, together with the
large investigation conducted by Nieuwenhuis et al. (2012) using
chronic schizophrenia subjects, have both yielded DAmeasures inferior
to those found by Koutsouleris et al. (2009, 2012), who also employed a
SVM-based neuroanatomical pattern classiﬁer to comparemoremodest
groups of mainly unmedicated ARMS individuals against healthy con-
trols. Interestingly, Koutsouleris et al. (2012) reported high classiﬁca-
tion accuracy in the comparison of ARMS subjects who subsequently
converted to full-blown psychosis versus healthy controls (92.3%), but
not between non-converters and controls (66.9%). It is conceivablezophrenia versus healthy controls as seen in the gray matter (A), white matter (B) and
n were overlaid on to the single-brain MNI template. The relative importance of each
1, reﬂected in the color brightness of each cluster. The red clusters (positive) indicate
ative) show regions of volumetric decrease in the patients compared to controls. Images
side of the ﬁgure).
Fig. 5. 3D rendering showing the top 10% ranked gray matter (A), white matter (B) and ventricular (C) morphometric features which contributed the most for the discrimination
between ﬁrst-episode schizophrenia and healthy controls. The relative importance of each region for between-group discrimination is translated here in a scale ranging from−1 to 1,
reﬂected in the color brightness of each cluster. The red clusters (positive) indicate regions of volumetric increase in patients relative to controls, whereas the blue clusters (negative)
show regions of volumetric decrease in the patients compared to controls.
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excess of subjects who already present clear brain structural abnormal-
ities than in samples of subjects who have full-blow psychosis but
which include not only individuals who had prodromal symptoms but
also others with a more abrupt onset of psychosis (DeLisi et al., 1998).
This would be consistent with the ﬁndings of retrospective clinical stud-
ies which have indicated that schizophrenia patients with antecedents
of clearly deﬁned and long-lasting prodromal symptoms display more
severe symptoms and social function impairments at follow-up when
compared to schizophrenia patients with a more abrupt onset of psy-
chotic features (van Mastrigt and Addington, 2002).
The high-dimensional discriminative morphological map compar-
ing ﬁrst-episode schizophrenia patients and healthy controls revealed
a complex pattern of regional volumetric abnormalities affecting both
gray and white matter fronto-temporo-occipital regions bilaterally,
including the inferior fronto-occipital fasciculus, as well as the third
and lateral ventricles. This pattern is consistent with previous studies
employing high-dimensional morphometry to study patients with
chronic schizophrenia and their unaffected relatives (Davatzikos etTable 4
Top 10% ranked gray matter (GM) morphometric features which most signiﬁcantly contrib
Gray matter region Volumetric increase
or decreasea
Anterior cingulate cortex Increase
Left frontal gyrus Decrease
Inferior frontal gyrus Decrease
Posterior orbital gyrus Decrease
Insular gyrus Decrease
Superior temporal gyrus Decrease
Insular gyrus Decrease
Posterior cingulate cortex Decrease
Middle temporal gyrus Decrease
Middle temporal, inferior temporal and fusiform gyri Decrease
Inferior temporal gyrus Decrease
Superior temporal gyrus Increase
Superior frontal gyrus and posterior cingulate cortex Decrease
Precentral gyrus Decrease
Postcentral gyrus Decrease
Precentral gyrus Decrease
Precentral gyrus and posterior cingulate cortex Decrease
Superior temporal gyrus (posterior portion) Decrease
Superior temporal gyrus (posterior portion) Decrease
Superior parietal lobule Decrease
Fusiform gyrus Decrease
Temporal-occipital junction Decrease
Temporal-occipital junction Decrease
GM, gray matter.
a First-episode schizophrenia patients relative to healthy controls.al., 2005; Fan et al., 2007, 2008), as well as with meta-analyses of
voxel-based morphometry (VBM) and diffusion tensor imaging stud-
ies of ﬁrst-episode schizophrenia (Bora et al., 2011). As expected, the
high-dimensional and multivariate nature of the present analysis un-
covered a greater number of clusters of gray and white matter volume
abnormalities than previously observed with VBM in this same sam-
ple (Colombo et al., 2012; Schaufelberger et al., 2007), although
there are some overlapping ﬁndings, particularly regarding to the in-
volvement of the bilateral prefrontal cortex, left superior temporal
gyrus and bilateral insula.
Based on previous studies, we predicted that the SVM classiﬁer
would be capable of distinguishing between schizophrenia patients
with better versus worse prognoses. In the only study published to
date attempting to use neuroanatomical pattern classiﬁcation to pre-
dict prognosis of psychotic disorders, Mourao-Miranda et al. (2012)
used a linear SVM classiﬁer to assess 6-year outcome in a sample of
subjects with ﬁrst-episode psychosis, and reported modest discrimi-
nation between ﬁrst-episode psychosis patients who later showed
continuous (n=28) versus episodic (n=28) course (overall accuracy=uted for the discrimination between ﬁrst-episode schizophrenia and healthy controls.
Hemisphere MNI Coordinates (central voxel) No. of Voxels
x y z
Right 13 35.5 4 831
Left −47.5 29.5 26 183
Right 38 20 17.5 153
Right 21 15 −17 146
Right 31 15 −18 69
Right 41.5 14 −15.5 151
Left −35 13 −14 412
Left −7 −0.5 52 140
Left −55 −4.5 −19.5 74
Right 47 −5.5 −36 949
Left −47 −11 −42 260
Left −56 −11 −1 151
Left −9 −11.5 53 251
Left −24 −22 49 245
Left −36.5 −23 48.5 318
Left −11 −26 54 72
Left −0.5 −27 56 165
Right 49.5 −40.5 5 65
Left −64 −41 3 158
Left −13.5 −41.5 58 275
Right 38 −44.5 −1 198
Right 40 −56.5 7 318
Left −62 −62.5 −3.5 135
Table 5
Top 10% ranked white matter (WM) morphometric features which most signiﬁcantly contributed for the discrimination between ﬁrst-episode schizophrenia and healthy controls.
White Matter Region/ Tract Volumetric Increase or Decreasea Hemisphere MNI coordinates (central voxel) No. of Voxels
x y z
Superior frontal gyrus WM Increase Right 12 62 2 73
Anterior Frontal WMb Increase Right 37 44 4.5 140
Anterior Frontal WMb Increase Left −37 41 −1 427
Inferior frontal gyrus WM Decrease Right 36 19 20 355
Frontal portion of CC (body) Decrease Right 16.5 19 25 346
Inferior frontal gyrus WM Decrease Left −32 19 21 211
Inferior temporal WMc Increase Left −46.5 −8 −43 99
Superior temporal gyrus WM Increase Left −55 −11.5 2.5 318
Superior parietal lobule WM Increase Left −55 −20.5 40.5 190
Cuneus WM/ Occipital portion of the CC Decrease Left −12 −78 14 443
WM, white matter; CC, corpus callosum.
a First-episode schizophrenia patients relative to healthy controls.
b Involving the middle/ inferior frontal gyri WM and the frontal portion of the inferior fronto-occipital fasciculus.
c Involving the middle/ inferior temporal gyri WM and the temporal portion of the inferior longitudinal fasciculus.
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be interpreted with caution, as the 2 ﬁrst-episode psychosis groups
(with continuous or episodic course) were unbalanced for 2 important
confounding variables: years of education and speciﬁc diagnosis
(for instance, 86% of the continuous course group patients were diag-
nosed as having schizophrenia compared to only 25% of the episodic
course group) (Mourao-Miranda et al., 2012). Nevertheless, our SVM-
classiﬁer failed to predict 1-year outcome (remission versus non-
remission) of ﬁrst-episode schizophrenia patients. This might be at
least partially explained by the small sample size of remitted patients’
group (n=15) and the subsequent risk of type II statistical errors. It
should also beweighted that a follow-up of 1 yearmight be insufﬁcient
to reliably deﬁne outcome in schizophrenia. Also, it is interesting to no-
tice that, whenwe repeated the analysis after excluding the schizophre-
nia patients with remitting course at follow-up, the classiﬁcation
performance substantially worsened (DA=64.3%). This is probably
due to loss of statistical power related to the smaller sample size.
There are a number of methodological limitations that should be
weighted in the interpretation of our results. Firstly, a signiﬁcant pro-
portion of our ﬁrst-episode schizophrenia patients (64.5%) were using
antipsychotic medication at the day of MRI scanning. This is similar to
the proportion reported in most studies that recruited samples of
ﬁrst-episode schizophrenia and in addition, the time of exposure for
those patients who were using antipsychotic drugs was relatively
short. Nevertheless, long-term antipsychotic treatment is associated
with both gray and white matter reductions (Ho et al., 2011) and,
thus, might have inﬂuenced our results. Secondly, comorbid substance
abuse or dependence is another important confounding variable in
the assessment of regional brain volumes (Colombo et al., 2012) and
the fact that a substantial proportion of the patients enrolled in our
study presented a positive history of substance misuse could have lim-
ited the sensitivity of the classiﬁer to identify morphometric abnormal-
ities speciﬁcally associated with the schizophrenia diagnosis. Finally,
the present sample was acquired using two MRI scanners. However,
the two scanners and acquisition protocols were identical, and a similar
proportion of schizophrenia patients and healthy controls were exam-
ined in each equipment. Thus, it is unlikely that this factor might have
inﬂuenced our results.
5. Conclusion
At the population level and using a “real world” sample of ﬁrst-
episode schizophrenia with comorbid substance use disorders and
heterogeneous disease course, the application of a neuroanatomical
pattern classiﬁer afforded only modest discrimination between ﬁrst-
episode schizophrenia patients and demographically matched, next-
door healthy controls recruited using an epidemiological approach.Also, we failed to predict the 1-year prognosis (i.e., remitting versus
non-remitting course) of ﬁrst-episode schizophrenia.
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